Nephros (NASDAQ:NEPH) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS

Nephros (NASDAQ:NEPH) posted its quarterly earnings data on Thursday. The company reported $0.05 earnings per share for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03, FiscalAI reports. Nephros had a return on equity of 11.97% and a net margin of 8.86%. The firm had revenue of $5.62 million for the quarter, compared to analysts’ expectations of $5.49 million.

Here are the key takeaways from Nephros’ conference call:

• Revenue and profitability grew: Third-quarter revenue rose 18% year over year to $5.6 million, while nine-month revenue increased 20% to $16.9 million. Nine-month net income grew to $1.8 million from $1.1 million, and adjusted EBITDA rose to $2.0 million from $1.4 million.
• Recurring business and customer reach expanded: Core programmatic revenue grew 19% for the first nine months, and active customer sites reached a record 1,766. Management said repeat orders and new installations support future replacement-filter demand.
• Gross margins came under pressure: Third-quarter gross margin fell to 58% from 61%, with higher inventory, shipping, handling and tariff costs, as well as a greater share of lower-margin service revenue, contributing to the decline. Management said it is working on pricing, sourcing, freight and operational efficiency.
• Nephros is pursuing broader markets and services: Healthcare remained its core market, while commercial and industrial customers accounted for 17% of new sites in the quarter. Management is also investing in service and education to support adoption and identify new product opportunities, though it said education’s return is still being evaluated.

Nephros Stock Performance

Shares of NEPH traded down $0.30 during mid-day trading on Friday, hitting $2.79. 104,011 shares of the stock were exchanged, compared to its average volume of 46,256. The company has a market cap of $30.33 million, a PE ratio of 15.50 and a beta of 1.76. The firm has a 50-day moving average of $3.79 and a two-hundred day moving average of $3.65. Nephros has a 52-week low of $2.66 and a 52-week high of $6.42.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on NEPH. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Nephros in a report on Friday, October 30th. Benchmark reaffirmed a “speculative buy” rating on shares of Nephros in a research note on Tuesday, August 18th. Zacks Research raised Nephros to a “hold” rating in a research note on Monday, July 20th. Finally, Northland Securities began coverage on Nephros in a report on Friday, July 17th. They issued a “market perform” rating and a $4.00 price target on the stock. One equities research analyst has rated the stock with a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat.com, Nephros presently has an average rating of “Hold” and a consensus price target of $4.00.

Nephros Company Profile

Nephros, Inc is a medical device company that develops and sells filtration products designed to improve water quality and reduce the risk of waterborne contamination. Its technologies are based primarily on ultrafiltration membranes that remove bacteria, viruses, endotoxins, cysts and other impurities from water.

The company serves the healthcare market with filtration systems for hemodialysis and infection-control applications. Its products are designed for use in hospitals, dialysis centers and other healthcare facilities where purified water is important for patient care and clinical operations.

Nephros also offers commercial water-filtration products for applications such as foodservice, hospitality, commercial buildings and healthcare facilities.